247 related articles for article (PubMed ID: 27749780)
1. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
Taks M; Pijls PA; Derijks LJ; Ten Broeke R; Grouls RJ; Curvers J; Gilissen LP
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):169-173. PubMed ID: 27749780
[TBL] [Abstract][Full Text] [Related]
2. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A
PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
[TBL] [Abstract][Full Text] [Related]
4. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
[TBL] [Abstract][Full Text] [Related]
5. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Lo Pumo S; Brunacci M; De Bortoli N; Jain A; Tolone S; Savarino E
Dig Liver Dis; 2018 May; 50(5):452-456. PubMed ID: 29274766
[TBL] [Abstract][Full Text] [Related]
6. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
[TBL] [Abstract][Full Text] [Related]
7. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
8. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
[No Abstract] [Full Text] [Related]
9. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease.
Guiotto C; Daperno M; Frigerio F; Vizzini M; Cerruti R; Ercole E; Cosimato M; Lavagna A; Germano L; Migliardi M; Rocca R
Dig Liver Dis; 2016 Feb; 48(2):138-43. PubMed ID: 26614644
[TBL] [Abstract][Full Text] [Related]
10. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
Lee LY; Sanderson JD; Irving PM
Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
[TBL] [Abstract][Full Text] [Related]
11. Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect.
Raffáč Š; Gombošová L; Gabzdilová J; Novotná L; Šajtyová K; Pekárová T; Kopolovets I; Tóth Š
Neuro Endocrinol Lett; 2017 Nov; 38(Suppl1):5-9. PubMed ID: 29200248
[TBL] [Abstract][Full Text] [Related]
12. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
[TBL] [Abstract][Full Text] [Related]
14. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
[TBL] [Abstract][Full Text] [Related]
15. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
16. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Lee JH; Choe YH
Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
18. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
Huang VW; Prosser C; Kroeker KI; Wang H; Shalapay C; Dhami N; Fedorak DK; Halloran B; Dieleman LA; Goodman KJ; Fedorak RN
Inflamm Bowel Dis; 2015 Jun; 21(6):1359-67. PubMed ID: 25989340
[TBL] [Abstract][Full Text] [Related]
19. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]